---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-070864"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-06-13T23:59:59+00:00"
generated_at: "2026-06-14T01:57:54.759212+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Immunome shareholders reject officer exculpation amendment at annual meeting

## Summary
- Class III directors Richard A. Baron and Philip Wagenheim elected until 2026.
- Proposal to amend certificate for officer exculpation failed: 3,528,592 for, 86,542 against, 4,115,553 broker non-votes.
- Ratification of Ernst & Young as independent auditor for FY2023 approved: 7,578,396 for, 153,921 against.
- Annual meeting held on June 7, 2023; quorum of 7,735,458 shares present.

## SEC filing metadata
- accession: 0001104659-23-070864
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-06-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923070864/0001104659-23-070864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923070864/tm2318518d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-070864
- JSON: https://secwatch.observer/filing/0001104659-23-070864.json
- Plain text: https://secwatch.observer/filing/0001104659-23-070864.txt

## Key facts
- Shareholder Votes
  Immunome Inc. shareholders rejected Amendment to Our Amended and Restated Certificate of Incorporation to Reflect New Delaware Law Provisions Regarding Officer Exculpation at the 2023-06-07 meeting.
  - Proposal: charter amendment
  - Outcome: failed
  - Meeting: 2023-06-07
  source text: Proposal 2: Amendment to Our Amended and Restated Certificate of Incorporation to Reflect New Delaware Law Provisions Regarding Officer Exculpation The amendment of the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation was not approved by an affirmative vote of a majority of the shares of common stock outstanding and entitled to vote at the Annual Meeting, with the following votes tabulated: For Against Abstain Broker Non-Vote Total 3,528,592 86,542 4,771 4,115,553 7,735,458
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923070864/0001104659-23-070864-index.htm
- Shareholder Votes
  Immunome Inc. shareholders approved Election of Class III Directors for a Three-Year Term Expiring in 2026 at the 2023-06-07 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: Proposal 1: Election of Class III Directors for a Three-Year Term Expiring in 2026 The following three nominees were elected to serve as Class III directors until the 2026 Annual Meeting of Stockholders of the Company and until their respective successors are elected and qualified, with the following votes tabulated: For Withheld Broker Non-Vote Total Richard A. Baron 2,897,767 722,138 4,115,553 7,735,458 Philip Wagenheim 3,287,880 332,025 4,115,553 7,735,458
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923070864/0001104659-23-070864-index.htm
- Shareholder Votes
  Immunome Inc. shareholders approved Ratification of the Selection of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2023 at the 2023-06-07 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: Proposal 3: Ratification of the Selection of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2023 The selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2023 was ratified, with the following votes tabulated: For Against Abstain Total 7,578,396 153,921 3,141 7,735,458
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923070864/0001104659-23-070864-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.